These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 24324698

  • 1. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
    Yoshihara D, Kugita M, Sasaki M, Horie S, Nakanishi K, Abe T, Aukema HM, Yamaguchi T, Nagao S.
    PLoS One; 2013; 8(12):e81480. PubMed ID: 24324698
    [Abstract] [Full Text] [Related]

  • 2. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
    Yoshihara D, Kurahashi H, Morita M, Kugita M, Hiki Y, Aukema HM, Yamaguchi T, Calvet JP, Wallace DP, Nagao S.
    Am J Physiol Renal Physiol; 2011 Feb; 300(2):F465-74. PubMed ID: 21147840
    [Abstract] [Full Text] [Related]

  • 3. Renin-angiotensin system activation in congenital hepatic fibrosis in the PCK rat model of autosomal recessive polycystic kidney disease.
    Goto M, Hoxha N, Osman R, Wen J, Wells RG, Dell KM.
    J Pediatr Gastroenterol Nutr; 2010 Jun; 50(6):639-44. PubMed ID: 20400910
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
    Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Masyuk AI, Gradilone SA, Gajdos GB, Chandok N, Bakeberg JL, Ward CJ, Ritman EL, Kiyokawa H, LaRusso NF.
    Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
    [Abstract] [Full Text] [Related]

  • 5. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
    Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF.
    Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431
    [Abstract] [Full Text] [Related]

  • 6. Disease stage characterization of hepatorenal fibrocystic pathology in the PCK rat model of ARPKD.
    Mason SB, Liang Y, Sinders RM, Miller CA, Eggleston-Gulyas T, Crisler-Roberts R, Harris PC, Gattone VH.
    Anat Rec (Hoboken); 2010 Aug; 293(8):1279-88. PubMed ID: 20665806
    [Abstract] [Full Text] [Related]

  • 7. Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease.
    Jia G, Kwon M, Liang HL, Mortensen J, Nilakantan V, Sweeney WE, Park F.
    Pediatr Nephrol; 2010 Jun; 25(6):1139-46. PubMed ID: 20229187
    [Abstract] [Full Text] [Related]

  • 8. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.
    Gradilone SA, Masyuk TV, Huang BQ, Banales JM, Lehmann GL, Radtke BN, Stroope A, Masyuk AI, Splinter PL, LaRusso NF.
    Gastroenterology; 2010 Jul; 139(1):304-14.e2. PubMed ID: 20399209
    [Abstract] [Full Text] [Related]

  • 9. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease.
    Lager DJ, Qian Q, Bengal RJ, Ishibashi M, Torres VE.
    Kidney Int; 2001 Jan; 59(1):126-36. PubMed ID: 11135065
    [Abstract] [Full Text] [Related]

  • 10. The renin-angiotensin system and hypertension in autosomal recessive polycystic kidney disease.
    Goto M, Hoxha N, Osman R, Dell KM.
    Pediatr Nephrol; 2010 Dec; 25(12):2449-57. PubMed ID: 20798958
    [Abstract] [Full Text] [Related]

  • 11. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease.
    Kugita M, Nishii K, Yamaguchi T, Suzuki A, Yuzawa Y, Horie S, Higashihara E, Nagao S.
    PLoS One; 2017 Dec; 12(5):e0177934. PubMed ID: 28542433
    [Abstract] [Full Text] [Related]

  • 12. Feeding soy protein isolate and n-3 PUFA affects polycystic liver disease progression in a PCK rat model of autosomal polycystic kidney disease.
    Maditz KH, Benedito VA, Oldaker C, Nanda N, Lateef SS, Livengood R, Tou JC.
    J Pediatr Gastroenterol Nutr; 2015 Apr; 60(4):467-73. PubMed ID: 25822773
    [Abstract] [Full Text] [Related]

  • 13. Metformin slows liver cyst formation and fibrosis in experimental model of polycystic liver disease.
    Sato Y, Qiu J, Hirose T, Miura T, Sato Y, Kohzuki M, Ito O.
    Am J Physiol Gastrointest Liver Physiol; 2021 Apr 01; 320(4):G464-G473. PubMed ID: 33439105
    [Abstract] [Full Text] [Related]

  • 14. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions.
    Arozal W, Watanabe K, Veeraveedu PT, Ma M, Thandavarayan RA, Sukumaran V, Suzuki K, Kodama M, Aizawa Y.
    Toxicology; 2011 Jan 11; 279(1-3):91-9. PubMed ID: 20888384
    [Abstract] [Full Text] [Related]

  • 15. B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.
    Holditch SJ, Schreiber CA, Harris PC, LaRusso NF, Ramirez-Alvarado M, Cataliotti A, Torres VE, Ikeda Y.
    Kidney Int; 2017 Sep 11; 92(3):657-668. PubMed ID: 28416225
    [Abstract] [Full Text] [Related]

  • 16. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD).
    Banales JM, Masyuk TV, Gradilone SA, Masyuk AI, Medina JF, LaRusso NF.
    Hepatology; 2009 Jan 11; 49(1):160-74. PubMed ID: 19065671
    [Abstract] [Full Text] [Related]

  • 17. Effects of Long-Term Exercise on Liver Cyst in Polycystic Liver Disease Model Rats.
    Sato Y, Qiu J, Miura T, Kohzuki M, Ito O.
    Med Sci Sports Exerc; 2020 Jun 11; 52(6):1272-1279. PubMed ID: 31880641
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of Mast Cell Degranulation With Cromolyn Sodium Exhibits Organ-Specific Effects in Polycystic Kidney (PCK) Rats.
    Jiang L, Fang P, Septer S, Apte U, Pritchard MT.
    Int J Toxicol; 2018 Jun 11; 37(4):308-326. PubMed ID: 29862868
    [Abstract] [Full Text] [Related]

  • 19. Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD.
    Park F, Sweeney WE, Jia G, Akbulut T, Mueller B, Falck JR, Birudaraju S, Roman RJ, Avner ED.
    Am J Physiol Renal Physiol; 2009 Mar 11; 296(3):F575-82. PubMed ID: 19129252
    [Abstract] [Full Text] [Related]

  • 20. Initial evaluation of hepatic T1 relaxation time as an imaging marker of liver disease associated with autosomal recessive polycystic kidney disease (ARPKD).
    Gao Y, Erokwu BO, DeSantis DA, Croniger CM, Schur RM, Lu L, Mariappuram J, Dell KM, Flask CA.
    NMR Biomed; 2016 Jan 11; 29(1):84-9. PubMed ID: 26608869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.